Drug Trial Radar · NCT03092102
The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects
Last checked: Nov 19, 2026Latest source record: Jul 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
136
Actual
Start
May 20, 2017
Primary completion
Feb 25, 2019
Study completion Feb 25, 2019
Sponsor
- Lead sponsor
- Sunshine Lake Pharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 27, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The Safety, Tolerability and Pharmacokinetic Study of idiopathic pulmonary fibrosis treatment drug HEC585 in Healthy Male and Female Subjects
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
HEC585Drug
HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: Predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144,and 216 h
- (AUC0-∞)Time frame: Predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120,144,and 216 h
- tmaxTime frame: Predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144,and 216 h
- Vz/FTime frame: Predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120,144,and 216 h
- t½Time frame: Predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144,and 216 h
- CL/FTime frame: Predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144,and 216 h
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Covance Clinical Research Unit, Inc.
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.